CY1112716T1 - Συνδυαστικο φαρμακο το οποιο περιεχει προβουκολη και παραγωγο τετραζολυλαλκοξυ-διυδροκαρβοστυριλιου με αποτελεσματα καταστολεα υπεροξειδιου - Google Patents

Συνδυαστικο φαρμακο το οποιο περιεχει προβουκολη και παραγωγο τετραζολυλαλκοξυ-διυδροκαρβοστυριλιου με αποτελεσματα καταστολεα υπεροξειδιου

Info

Publication number
CY1112716T1
CY1112716T1 CY20121100376T CY121100376T CY1112716T1 CY 1112716 T1 CY1112716 T1 CY 1112716T1 CY 20121100376 T CY20121100376 T CY 20121100376T CY 121100376 T CY121100376 T CY 121100376T CY 1112716 T1 CY1112716 T1 CY 1112716T1
Authority
CY
Cyprus
Prior art keywords
results
tetrazolylcoxy
provocaculate
didobarcobyril
combinant
Prior art date
Application number
CY20121100376T
Other languages
English (en)
Inventor
Ki Whan Hong
Tomohiro Yoshikawa
Of Korea Republic
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY1112716T1 publication Critical patent/CY1112716T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Αυτή η εφεύρεση αναφέρεται σε ένα συνδυαστικό φάρμακο το οποίο περιέχει ένα συνδυασμό τετραζολυλ-αλκοξυ-διυδροξυ-καρβοστυριλίου του τύπου:
CY20121100376T 2005-09-15 2012-04-20 Συνδυαστικο φαρμακο το οποιο περιεχει προβουκολη και παραγωγο τετραζολυλαλκοξυ-διυδροκαρβοστυριλιου με αποτελεσματα καταστολεα υπεροξειδιου CY1112716T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71695405P 2005-09-15 2005-09-15
US76177506P 2006-01-25 2006-01-25
EP06810355A EP1942895B1 (en) 2005-09-15 2006-09-14 Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects

Publications (1)

Publication Number Publication Date
CY1112716T1 true CY1112716T1 (el) 2016-02-10

Family

ID=37420867

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100376T CY1112716T1 (el) 2005-09-15 2012-04-20 Συνδυαστικο φαρμακο το οποιο περιεχει προβουκολη και παραγωγο τετραζολυλαλκοξυ-διυδροκαρβοστυριλιου με αποτελεσματα καταστολεα υπεροξειδιου

Country Status (21)

Country Link
US (2) US8580818B2 (el)
EP (2) EP2275106A1 (el)
JP (2) JP5179354B2 (el)
KR (1) KR101299320B1 (el)
AR (1) AR057520A1 (el)
AU (1) AU2006289752B2 (el)
BR (1) BRPI0616223A2 (el)
CA (1) CA2620296C (el)
CY (1) CY1112716T1 (el)
DK (1) DK1942895T3 (el)
ES (1) ES2378896T3 (el)
HK (1) HK1122996A1 (el)
IL (1) IL189751A0 (el)
MY (1) MY145787A (el)
NO (1) NO20081811L (el)
PL (1) PL1942895T3 (el)
PT (1) PT1942895E (el)
RU (1) RU2411945C2 (el)
SG (1) SG165379A1 (el)
TW (1) TWI372053B (el)
WO (1) WO2007032557A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065588A1 (es) * 2007-03-09 2009-06-17 Otsuka Pharma Co Ltd Un medicamento para tratar enfermedad pulmonar obstructiva cronica
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPH04193836A (ja) * 1990-11-26 1992-07-13 Banyu Pharmaceut Co Ltd 抗高脂血症剤
JPH107590A (ja) 1996-06-24 1998-01-13 Chugai Pharmaceut Co Ltd 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
EP0946178A4 (en) 1996-09-18 2003-05-07 Merck & Co Inc COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU1387399A (en) * 1997-11-10 1999-05-31 Vyrex Corporation Probucol esters and uses thereof
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
AU5965399A (en) 1998-10-12 2000-05-01 Andreas Bockelmann Pharmaceutically active composition
AU4671101A (en) 2000-04-10 2001-10-23 Malcolm R. Law Formulation for the prevention of cardiovascular disease
US20020115728A1 (en) * 2000-09-05 2002-08-22 Roland Stocker Compositions and methods for treating cardiovascular disorders
CZ20032031A3 (cs) * 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003192573A (ja) 2001-12-25 2003-07-09 Otsuka Pharmaceut Factory Inc 経口ゲル製剤
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
JP2005232059A (ja) * 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
CN101193656B (zh) 2005-06-08 2011-03-02 兴和株式会社 甘油三酸酯降低剂
JP4193836B2 (ja) 2005-10-24 2008-12-10 ブラザー工業株式会社 インク噴射装置の製造方法

Also Published As

Publication number Publication date
RU2008114512A (ru) 2009-10-20
IL189751A0 (en) 2008-12-29
US8580818B2 (en) 2013-11-12
WO2007032557A1 (en) 2007-03-22
PT1942895E (pt) 2012-03-29
AU2006289752B2 (en) 2011-06-09
MY145787A (en) 2012-04-30
CA2620296A1 (en) 2007-03-22
ES2378896T3 (es) 2012-04-18
US20140045889A1 (en) 2014-02-13
EP2275106A1 (en) 2011-01-19
JP5179354B2 (ja) 2013-04-10
AR057520A1 (es) 2007-12-05
TWI372053B (en) 2012-09-11
KR101299320B1 (ko) 2013-09-03
HK1122996A1 (en) 2009-06-05
CA2620296C (en) 2013-10-22
TW200744597A (en) 2007-12-16
EP1942895B1 (en) 2012-02-01
JP2013014605A (ja) 2013-01-24
KR20080049822A (ko) 2008-06-04
DK1942895T3 (da) 2012-03-05
EP1942895A1 (en) 2008-07-16
BRPI0616223A2 (pt) 2011-06-14
SG165379A1 (en) 2010-10-28
PL1942895T3 (pl) 2012-07-31
NO20081811L (no) 2008-04-14
JP5603393B2 (ja) 2014-10-08
RU2411945C2 (ru) 2011-02-20
AU2006289752A1 (en) 2007-03-22
JP2009508804A (ja) 2009-03-05
US20090176826A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
CY1113435T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1110489T1 (el) Παραγωγα ισοκινολινης
CY1119618T1 (el) Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας
CY1117681T1 (el) Ρυθμιστες 2,3-διοξυγενασης ινδολοαμινης και μεθοδοι χρησης αυτων
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CY1119979T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν τοξοειδη α και β toy clostridium difficile
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
CY1111269T1 (el) Ρυθμιστες βενζιμιδαζολης του vr1
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1118156T1 (el) Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
CY1114543T1 (el) Παραγωγο υποκατεστημενου οξινδολιου και χρηση αυτου ως συνδετηρα υποδοχεα αγγειοπιεσινης
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CY1116048T1 (el) Μια κρυσταλλικη μορφη τιγεκυκλινης και διαδικασιες για την παρασκευη της
CY1117956T1 (el) N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης
DOP2009000235A (es) Aril pirrolidinas insecticidas
CY1115994T1 (el) Φαρμακευτικες τυποποιησεις οι οποιες περιεχουν προσδεματα υποδοχεα ντοπαμινης